More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura

References

• George JN. How I treat patients with thrombotic thrombocytopenic purpura. Blood. 2010;116(20):4060–9. doi: 10.1182/blood-2010-07-271445
   PubMed Web of Science ®Google Scholar
• Amorosi E, Ultmann J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(2):139–59. doi: 10.1097/00005792-196603000-00003
   Web of Science ®Google Scholar
• Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med. 1991;325(6):393–7. doi: 10.1056/NEJM199108083250604
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500–11; quiz 662. doi: 10.1182/blood-2009-09-243790
   PubMed Web of Science ®Google Scholar
• Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264–83. doi: 10.1111/j.1600-065X.2010.00945.x
   PubMed Web of Science ®Google Scholar
• Provan D, Newland AC, Amadori S, Stasi R. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;143(2):294; author reply 5. doi: 10.1111/j.1365-2141.2008.07326.x
   PubMed Web of Science ®Google Scholar
• Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–61. doi: 10.1111/j.1365-2141.2006.06448.x
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol. 2010;89(10):1029–33. doi: 10.1007/s00277-010-0968-3
   PubMed Web of Science ®Google Scholar
• Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104–11. doi: 10.1097/CCM.0b013e31822e9d66
   PubMed Web of Science ®Google Scholar
• Pequeño-Luévano M, Villarreal-Martínez L, Jaime-Pérez JC, Gómez-de-León A, Cantú-Rodríguez OG, González-Llano O, et al. Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases. Hematology. 2013;18(4):233–6. doi: 10.1179/1607845412Y.0000000073
   PubMed Web of Science ®Google Scholar
• Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–53. doi: 10.1182/blood-2011-03-341131
   PubMed Web of Science ®Google Scholar
• Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11(3):481–90. doi: 10.1111/jth.12114
   PubMed Web of Science ®Google Scholar
• McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. doi: 10.1111/j.1538-7836.2010.03818.x
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119(16):3691–7. doi: 10.1182/blood-2011-06-363556
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–34. doi: 10.1111/j.1600-0609.2010.01486.x
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546–51. doi: 10.1111/ejh.12199
   PubMed Web of Science ®Google Scholar
• Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930–3. doi: 10.3324/haematol.12206
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494–500. doi: 10.1111/ejh.12102
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783–5. doi: 10.1182/blood-2010-06-291831
   PubMed Web of Science ®Google Scholar
• Benjamin M, Terrell DR, Vesely SK, Voskuhl GW, Dezube BJ, Kremer Hovinga JA, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(8):1129–37.
   Google Scholar
• Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura – favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153(4):515–9. doi: 10.1111/j.1365-2141.2011.08636.x
   PubMed Web of Science ®Google Scholar
• Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, et al. Preemtive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124(2):204. doi: 10.1182/blood-2014-01-550244
   PubMed Web of Science ®Google Scholar
• Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125(10):1526–31. doi: 10.1182/blood-2014-10-559211
   PubMed Web of Science ®Google Scholar